Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions. It is also involved in the development of generic topical dermatological drug products. Sol-Gel Technologies Ltd. has collaboration with Perrigo. The company was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
IPO Year: 2018
Exchange: NASDAQ
Website: sol-gel.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/19/2024 | $6.00 → $4.00 | Strong Buy → Outperform | Raymond James |
| 10/21/2022 | $5.50 | Hold | Jefferies |
| 11/15/2021 | $21.00 → $20.00 | Buy | HC Wainwright & Co. |
| 11/12/2021 | $23.00 → $21.00 | Strong Buy | Raymond James |
| 7/28/2021 | $20.00 → $21.00 | Buy | HC Wainwright & Co. |
| 7/12/2021 | $21.00 → $20.00 | Buy | HC Wainwright & Co. |
Live FDA approvals issued by the Food and Drug Administration and FDA breaking news
Submission status for SOL-GEL TECHNOLOGIES LTD's drug TWYNEO (ORIG-1) with active ingredient TRETINOIN;BENZOYL PEROXIDE has changed to 'Approval' on 07/26/2021. Application Category: NDA, Application Number: 214902, Application Classification: Type 4 - New Combination
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Fastest customizable press release news feed in the world
Raymond James downgraded Sol-Gel from Strong Buy to Outperform and set a new price target of $4.00 from $6.00 previously
Jefferies resumed coverage of Sol-Gel with a rating of Hold and set a new price target of $5.50
HC Wainwright & Co. reiterated coverage of Sol-Gel Technologies with a rating of Buy and set a new price target of $20.00 from $21.00 previously
Raymond James reiterated coverage of Sol-Gel Technologies with a rating of Strong Buy and set a new price target of $21.00 from $23.00 previously
HC Wainwright & Co. reiterated coverage of Sol-Gel Technologies with a rating of Buy and set a new price target of $21.00 from $20.00 previously
HC Wainwright & Co. reiterated coverage of Sol-Gel Technologies with a rating of Buy and set a new price target of $20.00 from $21.00 previously
6-K - Sol-Gel Technologies Ltd. (0001684693) (Filer)
SCHEDULE 13G - Sol-Gel Technologies Ltd. (0001684693) (Subject)
EFFECT - Sol-Gel Technologies Ltd. (0001684693) (Filer)
POS AM - Sol-Gel Technologies Ltd. (0001684693) (Filer)
6-K - Sol-Gel Technologies Ltd. (0001684693) (Filer)
SCHEDULE 13D/A - Sol-Gel Technologies Ltd. (0001684693) (Subject)
424B3 - Sol-Gel Technologies Ltd. (0001684693) (Filer)
6-K - Sol-Gel Technologies Ltd. (0001684693) (Filer)
6-K - Sol-Gel Technologies Ltd. (0001684693) (Filer)
EFFECT - Sol-Gel Technologies Ltd. (0001684693) (Filer)
NESS ZIONA, Israel, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase-3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, a Phase-1b, double blinded clinical trial of SGT-210 (erlotinib ointment, 5%) on Darier disease patients and with two approved large-category dermatology products, TWYNEO and EPSOLAY, announced today that on August 27, 2025 Health Canada issued a Notice of Compliance (NOC) for EPSOLAY for the treatment of inflammatory lesions of rosacea in adults. This approval comes as a result of Sol-Gel's partnership with Searchlig
Patient enrollment for our ongoing Phase-3 clinical trial of SGT-610 for Gorlin Syndrome has been completed; top-line results are expected in the fourth quarter of 2026Phase-1b proof-of-concept clinical trial of SGT-210 for Darier disease is ongoingSol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY and TWYNEO in the U.S. for a total consideration of $16 million to be received during 2025Following recent transactions, Sol-Gel's cash runway is expected to extend into the first quarter of 2027 NESS ZIONA, Israel, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting
NESS ZIONA, Israel, May 23, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a clinical-stage dermatology company, today announced financial results for the first quarter ended March 31, 2025. Financial Results for the First Quarter Year Ended March 31st, 2025 Total revenue in the first quarter was $1 million compared to $0.5 million revenues for the same period in 2024. Research and development expenses were $8.8 million compared to $5.3 million in the same period in 2024. The increase of $3.5 million was primarily attributed to an increase of $3.6 million due to expenses associated with supplier-led ma
NESS ZIONA, Israel, May 01, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (the "Company") (NASDAQ:SLGL), a clinical-stage dermatology company, today announced a reverse share split (the "Reverse Split") of the Company's issued and outstanding ordinary shares, par value NIS 0.1 per share (the "Ordinary Shares"), at the ratio of 10-for-1, such that each ten (10) Ordinary Shares shall be consolidated into one (1) Ordinary Share. The Company obtained shareholders' approval for the Reverse Split at a ratio of between 2:1 and 10:1 at a special meeting of shareholders, which took place on April 1, 2025. The Company's board of directors then approved the Reverse Split ratio of 10-for-1 on Ap
Sol-Gel to receive $16 million during 2025Cash runway is expected to extend into the first quarter of 2027; Company expects to have sufficient cash to complete its Phase III clinical trialSGT-610 Phase III clinical trial top-line results are expected in the fourth quarter of 2026; a significant milestone in the clinical trial of recruiting more than 80% of the patients has been achievedSol-Gel now estimates the U.S. market potential for SGT-610 to be between $400 to $500 million annuallySGT-210 Phase 1b trial in Darier patients is ongoing; 50% of the patients have already completed the trial NESS ZIONA, Israel, April 17, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL
NESS ZIONA, Israel, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved large-category dermatology products, TWYNEO® and EPSOLAY®, today announced that it has received an extension of the period to regain compliance with The Nasdaq Stock Market LLC's ("Nasdaq") minimum bid price rule. On November 19, 2024, the Company received a letter from Nasdaq notifying the Company that, while the Company has not regained compliance with the Minimum Bid Price Requirement, Nasdaq has d
Mori Arkin's appointment as interim CEO as of January 1, 2025 approved by shareholdersPhase 3 clinical trial of SGT-610 for Gorlin Syndrome is ongoing with over 40 clinical sites activatedSGT-210 proof-of-concept study in patients suffering from Darier disease is ongoing NESS ZIONA, Israel, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase-3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved large-category dermatology products, TWYNEO® and EPSOLAY®, today announced financial results for the third quarter ended September
Following recent transactions and cost-cutting efforts, Sol-Gel's cash runway is expected to extend into the first quarter of 2026Ongoing Phase 3 clinical trial of SGT-610 for Gorlin Syndrome with over 30 clinical sites activated; Top-line results are expected by the second quarter of 2026SGT-210 proof-of-concept study in patients suffering from Darier disease, a significant unmet medical need in dermatology, is ongoingSol-Gel sells its rights in the Abbreviated New Drug Application (ANDA)drug product generic to Zoryve® Cream(roflumilast cream 0.3%)Following management realignment, Mr. Mori Arkin, the Company's executive chairman and controlling shareholder to be appointed as Company's inter
NESS ZIONA, Israel, July 25, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved large-category dermatology products, TWYNEO® for the treatment of acne vulgaris and EPSOLAY® for the treatment of inflammatory lesions of rosacea, today announced it has entered into six (6) exclusive license agreements with MagnaPharm Trading Slovakia S.R.L, Galenica A.B, Leman SKL SA, InfectoPharm, Aspire Pharma Limited and Abex Pharmaceutica (PTY) Ltd. for the commercialization of TWYNEO and EPOSLAY
NESS ZIONA, Israel, July 15, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved large-category dermatology products, TWYNEO® and EPSOLAY®, today announced that the Chief Executive Officer, Dr. Alon Seri-Levy, has recently advised the Sol-Gel Board of Directors of his desire to step down from his position as CEO and member of the Board. The Company and Dr. Seri-Levy have agreed on the terms of Dr. Seri-Levy's separation from the Company and should these be approved by the Company's
Live Leadership Updates
Mori Arkin's appointment as interim CEO as of January 1, 2025 approved by shareholdersPhase 3 clinical trial of SGT-610 for Gorlin Syndrome is ongoing with over 40 clinical sites activatedSGT-210 proof-of-concept study in patients suffering from Darier disease is ongoing NESS ZIONA, Israel, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase-3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved large-category dermatology products, TWYNEO® and EPSOLAY®, today announced financial results for the third quarter ended September
Growth trends for TWYNEO and EPSOLAY continue to improve, demonstrating robust uptake by prescribersSol-Gel's cash runway expected to extend through the end of the first quarter of 2024 NESS ZIONA, Israel, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and generic topical drug products for the treatment of skin diseases, announced today financial results for the third quarter ended September 30, 2022 and provided a corporate update. Alon Seri-Levy, PhD, Chief Executive Officer of Sol-Gel, stated, "We are very pleased with the continu
NESS ZIONA, Israel, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and generic topical drug products for the treatment of skin diseases, announced today the appointment of Michael Glezin to the position of Vice President, Business Development. In this position, Mr. Glezin will be responsible for identifying new in-licensing business opportunities as well as potential commercial partners for the Company's approved products in ex-US territories. "We are very pleased to have Michael join the Company as we expand our business development efforts," stated Alon Seri-Levy,
Live finance-specific insights
An ongoing phase 3 clinical trial of SGT-610 for Gorlin Syndrome with the first patient screened; Results are expected by the end of 2025 Sol-Gel maintains a cash runway into the second half of 2025 NESS ZIONA, Israel, March 13, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company with an innovative pipeline and approaches to develop a pioneering treatment for patients with severe skin conditions, is conducting a phase 3 clinical trial of SGT-610 (Patidegib gel, 2%), an Orphan Drug candidate with the potential to be the first therapy for preventing new basal cell carcinomas in Gorlin syndrome and partnered with Galderma to commercialize two approved lar
Positive trends continue for TWYNEO® and EPSOLAY® with recurrent prescriber bases at 98% for TWYNEO and 92% for EPSOLAY during Q1 2023 Sol-Gel on track to advance Orphan Drug candidate, SGT-610 (patidegib) for Gorlin syndrome into Phase 3 testing in late 2023 Phase 1 trial for SGT-210 (erlotinib) demonstrated no systemic absorption-related adverse events; Sol-Gel intends to advance this drug candidate Sol-Gel has cash runway into the second half of 2025 NESS ZIONA, Israel, May 12, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company with two innovative dermatology products, EPSOLAY and TWYNEO, that were launched in the U.S., SGT-610, which is Phase 3
Recent acquisition of Phase 3-ready SGT-610 (patidegib), an Orphan Drug candidate, broadens Sol-Gel's pipeline with the potential to be the first therapy for preventing new basal cell carcinomas in Gorlin syndromeA Phase 3 study of SGT-610 is expected to initiate in the second half of 2023, with results expected by the end of 2025The base of recurrent TWYNEO® prescribers was 82% in Q4 2022, while the EPSOLAY® recurrent prescriber base has grown to 64% during the same periodFollowing recent financing, Sol-Gel's cash runway expected to extend into the second half of 2025 NESS ZIONA, Israel, March 10, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company wi
Patidegib, an Orphan Drug candidate, broadens Sol-Gel's pipeline with the potential to be the first therapy for preventing new basal cell carcinomas in Gorlin syndrome, if approved by the FDAPhase 3 study expected to initiate in the second half of 2023, with results expected by the end of 2025Conference call to be held this morning at 8:30 a.m. U.S. ET NESS ZIONA, Israel, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company with FDA approvals for EPSOLAY® and TWYNEO®, two innovative dermatology products that were launched in the U.S. by partner Galderma during 2022, announced today the acquisition of topically-applied patidegib, a hedgehog sig
NESS ZIONA, Israel, July 20, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, will report second quarter 2021 financial results on Wednesday, August 4, 2021 at 7:05 AM ET. About Sol-Gel Technologies Sol-Gel is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel leverages its proprietary microencapsulation technology platform for the development of TWYNEO® under investigation for
This live feed shows all institutional transactions in real time.
SC 13G/A - Sol-Gel Technologies Ltd. (0001684693) (Subject)
SC 13G/A - Sol-Gel Technologies Ltd. (0001684693) (Subject)
SC 13D/A - Sol-Gel Technologies Ltd. (0001684693) (Subject)
SC 13G - Sol-Gel Technologies Ltd. (0001684693) (Subject)
SC 13G/A - Sol-Gel Technologies Ltd. (0001684693) (Subject)
SC 13G - Sol-Gel Technologies Ltd. (0001684693) (Subject)
SC 13D/A - Sol-Gel Technologies Ltd. (0001684693) (Subject)
SC 13G/A - Sol-Gel Technologies Ltd. (0001684693) (Subject)
SC 13G - Sol-Gel Technologies Ltd. (0001684693) (Subject)
SC 13G/A - Sol-Gel Technologies Ltd. (0001684693) (Subject)